Evommune (EVMN) Accumulated Expenses (2024 - 2026)

Evommune (EVMN) posted quarterly Accumulated Expenses of $4.7 million for Q1 2026, down 4.05% quarter-over-quarter from $4.9 million in Q4 2025.

Evommune (EVMN) Accumulated Expenses (2024 - 2026) Analysis & Trends

Evommune (EVMN) has reported Accumulated Expenses for 3 consecutive years, with $4.7 million the latest figure, recorded in Q1 2026.

In Q1 2026, Accumulated Expenses changed N/A year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $4.7 million (changed N/A YoY), while the FY2025 annual figure was $4.9 million, up 35.77% from the prior year.
Accumulated Expenses fell to $4.7 million in Q1 2026 per EVMN's latest filing, from $4.9 million in the prior quarter.
Across five years, Accumulated Expenses topped out at $4.9 million in Q4 2025 and bottomed at $2.9 million in Q3 2025.
Historically, Accumulated Expenses has averaged $4.0 million across 3 years, with a median of $4.2 million in 2024.
On a YoY basis, Accumulated Expenses climbed as much as 35.77% in 2025 and fell as far as 35.77% in 2025.
Evommune's Accumulated Expenses stood at $3.6 million in 2024, then surged by 35.77% to $4.9 million in 2025, then dropped by 4.05% to $4.7 million in 2026.
Business Quant data shows EVMN's Accumulated Expenses at $4.7 million in Q1 2026, $4.9 million in Q4 2025, and $2.9 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Evommune	531.53 Mn	330.73 Mn	-

Download Data